PT-141 (Bremelanotide) Research & Studies
We track 20 published, PubMed-indexed studies for PT-141 (Bremelanotide), spanning 2016 to 2026. The research below includes 2 meta-analysiss, 12 reviews, 6 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
2
Meta-Analysiss
12
Reviews
6
Clinical Trials
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Meta-AnalysisToledo RG, Winkelman WD, et al.|J Minim Invasive Gynecol|2026
Novel Pharmacologic Treatments of Female Sexual Dysfunction.
ReviewHow A, Jowdy C, et al.|Clin Obstet Gynecol|2025
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
ReviewSpielmans GI, Ellefson EM|J Sex Res|2024
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
ReviewCipriani S, Alfaroli C, et al.|Expert Opin Pharmacother|2023
Targeting the central melanocortin system for the treatment of metabolic disorders.
ReviewSweeney P, Gimenez LE, et al.|Nat Rev Endocrinol|2023
Safety Profile of Bremelanotide Across the Clinical Development Program.
Clinical TrialClayton AH, Kingsberg SA, et al.|J Womens Health (Larchmt)|2022
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Clinical TrialSimon JA, Kingsberg SA, et al.|J Womens Health (Larchmt)|2022
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
ReviewEdinoff AN, Sanders NM, et al.|Neurol Int|2022
Medical Treatment of Female Sexual Dysfunction.
ReviewNappi RE, Tiranini L, et al.|Urol Clin North Am|2022
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.
ReviewPfaus JG, Sadiq A, et al.|CNS Spectr|2022
Pharmacotherapy for Sexual Dysfunction in Women.
ReviewLee JH, Lee JE, et al.|Curr Psychiatry Rep|2022
Pharmacologic therapeutic options for sexual dysfunction.
ReviewBurton CS, Mishra K|Curr Opin Obstet Gynecol|2022
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Meta-AnalysisSpielmans GI|J Sex Res|2021
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Clinical TrialKoochaki P, Revicki D, et al.|J Womens Health (Larchmt)|2021
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.
ReviewMintzes B, Tiefer L, Cosgrove L|Drug Ther Bull|2021
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
ReviewPettigrew JA, Novick AM|J Midwifery Womens Health|2021
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
ReviewMayer D, Lynch SE|Ann Pharmacother|2020
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Clinical TrialKingsberg SA, Clayton AH, et al.|Obstet Gynecol|2019
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Clinical TrialAlthof S, Derogatis LR, et al.|J Sex Med|2019
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clinical TrialClayton AH, Althof SE, et al.|Womens Health (Lond)|2016